Vaccination, immune and gene therapy based on virus-like particles against viral infections and cancer

被引：78

作者：

Ramqvist, Torbjorn ^{[1
]}

Andreasson, Kalle ^{[1
]}

Dalianis, Tina ^{[1
]}

机构：

[1] Canc Ctr Karolinska, Karolinska Inst, Dept Oncol Pathol, SE-17176 Stockholm, Sweden

来源：

EXPERT OPINION ON BIOLOGICAL THERAPY | 2007年 / 7卷 / 07期

关键词：

cancer; immunotherapy; vaccine; virus; virus-like particles;

D O I：

10.1517/14712598.7.7.997

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Virus-like particles (VLPs) are self-assembling, non-replicating particles lacking the viral genome that are formed by one or several viral structural proteins. VLPs can be purified after expression in yeast cells, insect cells using baculoviruses, Escherichia coli or mammalian cells. Recently, vaccines based on VLPs have come into focus with the FDA approval of a VLP-based vaccine against human papilloma viruses. However, this application of VLPs is just one of many developments within the VLP field. Other potential applications under development besides vaccines against viruses or cancers also include gene delivery and treatment of different disorders.

引用

页码：997 / 1007

页数：11

共 88 条

[1] A vaccine for hypertension based on virus-like particles:: preclinical efficacy and phase I safety and immunogenicity
Ambuehl, Patrice M.
Tissot, Alain C.
Fulurija, Alma
Maurer, Patrik
Nussberger, Juerg
Sabat, Robert
Nief, Vera
Schellekens, Charlotte
Sladko, Katja
Roubicek, Kirsten
Pfister, Thomas
Rettenbacher, Manfred
Volk, Hans-Dieter
Wagner, Frank
Mueller, Philipp
Jennings, Gary T.
Bachmann, Martin F.
[J]. JOURNAL OF HYPERTENSION, 2007, 25 (01) : 63 - 72
[2] Human papillomavirus vaccine update
Ames A.
Gravitt P.
[J]. Current Infectious Disease Reports, 2007, 9 (2) : 151 - 158
[3] Parvovirus B19 empty Capsids as antigen carriers for presentation of antigenic determinants of dengue 2 virus
Amexis, Georgios
Young, Neal S.
[J]. JOURNAL OF INFECTIOUS DISEASES, 2006, 194 (06) : 790 - 794
[4] Liver-targeted gene therapy by SV40-based vectors using the hydrodynamic injection method
Arad, U
Zeira, E
Abd El-Latif, M
Mukherjee, S
Mitchell, L
Pappo, O
Galun, E
Oppenheim, A
[J]. HUMAN GENE THERAPY, 2005, 16 (03) : 361 - 371
[5] Recombinant Norwalk virus-like particles given orally to volunteers: Phase I study
Ball, JM
Graham, DY
Opekun, AR
Gilger, MA
Guerrero, RA
Estes, MK
[J]. GASTROENTEROLOGY, 1999, 117 (01) : 40 - 48
[6] Immunogenicity and protective efficacy of rotavirus 2/6-virus-like particles produced by a dual baculovirus expression vector and administered intramuscularly, intranasally, or orally to mice
Bertolotti-Ciarlet, A
Ciarlet, M
Crawford, SE
Conner, ME
Estes, MK
[J]. VACCINE, 2003, 21 (25-26) : 3885 - 3900
[7] Murine polyomavirus-like particles induce maturation of bone marrow-derived dendritic cells and proliferation of T cells
Bickert, Thomas
Wohlleben, Gisela
Brinkman, Marc
Trujillo-Vargas, Claudia M.
Ruehland, Claus
Reiser, Christian O. A.
Hess, Juergen
Erb, Klaus J.
[J]. MEDICAL MICROBIOLOGY AND IMMUNOLOGY, 2007, 196 (01) : 31 - 39
[8] Beneficial therapeutic effects with different particulate structures of murine polyomavirus VP1-coat protein carrying self or non-self CD8 T cell epitopes against murine melanoma
Brinkman, M
Walter, J
Grein, S
Thies, MJW
Schulz, TW
Herrmann, M
Reiser, COA
Hess, J
[J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2005, 54 (06) : 611 - 622
[9] Baculovirus-derived human immunodeficiency virus type 1 virus-like particles activate dendritic cells and induce ex vivo T-cell responses
Buonaguro, L.
Tornesello, M. L.
Tagliamonte, M.
Gallo, R. C.
Wang, L. X.
Kamin-Lewis, R.
Abdelwahab, S.
Lewis, G. K.
Buonaguro, F. M.
[J]. JOURNAL OF VIROLOGY, 2006, 80 (18) : 9134 - 9143
[10] Induction of autoantibodies to CCR5 in macaques and subsequent effects upon challenge with an R5-tropic simian/human immunodeficiency virus
Chackerian, B
Briglio, L
Albert, PS
Lowy, DR
Schiller, JT
[J]. JOURNAL OF VIROLOGY, 2004, 78 (08) : 4037 - 4047

← 1 2 3 4 5 6 7 8 9 →